Company profile
Sarepta Therapeutics, Inc.
NASDAQ:SRPTBiotechnology: Pharmaceutical Preparations
Drug pipeline (8)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CASIMERSEN | approved | — | 1 | approved |
| ETEPLIRSEN | approved | — | 8 | approved |
| GOLODIRSEN | approved | — | 3 | approved |
| BIDRIDISTROGENE XEBOPARVOVEC | phase3 | — | 3 | active |
| PATIDISTROGENE BEXOPARVOVEC | phase1_2 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (49)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07536061 | phase1 | recruiting | 2026-05-12 | 2027-11-30 | Sarepta Therapeutics, Inc. | A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease |
| NCT05876780 | phase1 | active_not_recruiting | 2022-12-19 | 2028-08-28 | Sarepta Therapeutics, Inc. | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) |
| NCT05906251 | phase1 | terminated | 2023-05-22 | 2025-06-13 | Sarepta Therapeutics, Inc. | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) |
| NCT06241950 | phase1 | terminated | 2024-01-29 | 2025-10-10 | Sarepta Therapeutics, Inc. | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) |
| NCT05881408 | phase3 | active_not_recruiting | 2023-05-31 | 2027-05-31 | Sarepta Therapeutics, Inc. | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125781 | BLA | Sarepta Therapeutics, Inc. | ||||
Loading… | ||||||
| NDA 206488 | NDA | SAREPTA THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 211970 | NDA | SAREPTA THERAPEUTICS INC | ||||
Loading… | ||||||
| NDA 213026 | NDA | SAREPTA THERAPEUTICS INC | ||||
Loading… | ||||||